Haemophilus b conjugate vaccine (tetanus toxoid conjugate) - Biologic Drug Details

Summary for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Recent Clinical Trials for haemophilus b conjugate vaccine (tetanus toxoid conjugate)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all haemophilus b conjugate vaccine (tetanus toxoid conjugate) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for haemophilus b conjugate vaccine (tetanus toxoid conjugate) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)

Introduction

The Haemophilus b conjugate vaccine, also known as the tetanus toxoid conjugate vaccine, is a crucial biologic drug designed to prevent invasive diseases caused by Haemophilus influenzae type b (Hib). This vaccine has been a cornerstone in pediatric immunization programs globally, and its market dynamics are influenced by several key factors.

Rising Prevalence of Infectious Diseases

One of the primary drivers of the conjugate vaccine market, including the Haemophilus b conjugate vaccine, is the increasing incidence of infectious diseases worldwide. Hib infections pose a significant health risk, particularly to young children, the elderly, and immunocompromised individuals. The rising cases of pneumococcal, meningococcal, and Haemophilus influenzae type B infections have accelerated the demand for effective immunization solutions, driving the growth of the conjugate vaccines market[1][4].

Technological Advancements

Advancements in vaccine technology have significantly enhanced the efficacy and safety of conjugate vaccines. Innovations such as carrier protein optimization and nanoparticle delivery systems are improving immune responses and reducing the number of injections required. The development of multivalent vaccines that target multiple serotypes in a single dose is another key trend shaping the market[4].

Government-Led Immunization Programs

Government-supported vaccination programs and increased global immunization initiatives are bolstering the demand for conjugate vaccines. In regions like Asia-Pacific, government-led campaigns have increased awareness about infectious diseases and driven the adoption of conjugate vaccines, including the Haemophilus b conjugate vaccine[1][4].

Pediatric Immunization Demand

The demand for pediatric immunizations is a significant driver for the conjugate vaccines market. The Haemophilus b conjugate vaccine is recommended for all children from 2 months to 5 years of age, making it a staple in childhood vaccination schedules. The large pediatric population in regions like Asia-Pacific further fuels this demand[4].

Market Size and Growth

The global conjugate vaccine market, which includes the Haemophilus b conjugate vaccine, was estimated at USD 19.01 billion in 2023 and is expected to grow at a CAGR of 9.60% from 2024 to 2030. By 2032, the market is projected to reach USD 55.09 billion, growing at a CAGR of 12.55%[1][4].

Regional Growth

• Asia Pacific: This region is anticipated to witness the fastest growth, with a CAGR of 25.13% over the forecast period. Rapid urbanization, growing population density, and increasing healthcare expenditure are key drivers. Countries like China and India are experiencing a surge in vaccine demand due to rising awareness and government-led immunization campaigns[1].
• North America: This region leads the conjugate vaccines market, driven by high healthcare expenditure and advanced medical infrastructure. Increased awareness among patients about the benefits of vaccination is expected to further propel market growth[4].
• Europe: The presence of leading pharmaceutical companies and increased government support for vaccine development are set to accelerate market expansion in this region[4].

Cost-Benefit Analysis

The cost-benefit analysis of the Haemophilus b conjugate vaccine is highly favorable. For instance, a study in Chile showed that adding the Hib conjugate vaccine to the immunization program would prevent at least 1,229 cases of Hib invasive disease, including meningitis, and save the National Health Service over $403,225 over a 10-year period. The benefit/cost ratio was 1.66, indicating that the vaccine is cost-beneficial even at higher costs[2].

Key Players

Several major pharmaceutical companies are involved in the production and distribution of conjugate vaccines, including the Haemophilus b conjugate vaccine. Key players include Sanofi Pasteur Inc., Pfizer Inc., GSK plc, Merck & Co., Inc., and Serum Institute of India Pvt. Ltd.[1][4].

Challenges

Despite the robust growth, the conjugate vaccines market faces challenges such as high costs and supply chain issues. These hurdles can affect the widespread adoption of these vaccines, particularly in developing countries[4].

Clinical Significance

The Haemophilus b conjugate vaccine is an active immunizing agent that works by causing the body to produce antibodies against Hib bacteria. It prevents life-threatening illnesses such as meningitis, epiglottitis, pericarditis, pneumonia, and septic arthritis. The vaccine is administered in a series of doses, with booster doses available to maintain protection[5].

Conclusion

The Haemophilus b conjugate vaccine market is poised for significant growth driven by the rising prevalence of infectious diseases, advancements in vaccine technology, and government-led immunization initiatives. Despite challenges such as high costs and supply chain issues, the market is expected to expand rapidly, particularly in emerging regions.

Key Takeaways

• The global conjugate vaccine market, including the Haemophilus b conjugate vaccine, is expected to grow significantly due to rising infectious disease incidence.
• Technological advancements and multivalent vaccines are enhancing market growth.
• Government-led immunization programs and pediatric immunization demand are key drivers.
• Asia-Pacific is expected to witness the fastest growth due to rapid urbanization and increasing healthcare expenditure.
• Cost-benefit analyses show that the Haemophilus b conjugate vaccine is highly cost-effective.

FAQs

Q: What is the Haemophilus b conjugate vaccine used for? A: The Haemophilus b conjugate vaccine is used to prevent invasive diseases caused by Haemophilus influenzae type b (Hib), including meningitis, epiglottitis, and other serious infections[5].

Q: Who should receive the Haemophilus b conjugate vaccine? A: The vaccine is recommended for all children from 2 months to 5 years of age (up to the 6th birthday)[5].

Q: What is the expected growth rate of the conjugate vaccine market? A: The global conjugate vaccine market is expected to grow at a CAGR of 9.60% from 2024 to 2030 and reach USD 55.09 billion by 2032[1][4].

Q: Which region is expected to witness the fastest growth in the conjugate vaccine market? A: The Asia-Pacific region is anticipated to witness the fastest growth, with a CAGR of 25.13% over the forecast period[1].

Q: What are the challenges facing the conjugate vaccine market? A: High costs and supply chain issues are significant challenges affecting the widespread adoption of conjugate vaccines[4].

Sources

1. Grand View Research - Conjugate Vaccine Market Size, Share, Growth Report, 2030
2. PubMed - Cost-benefit analysis for the use of Haemophilus influenzae type b ...
3. FDA - ActHIB | FDA
4. Data Bridge Market Research - Conjugate Vaccines Market Size, Share, Growth & Outlook By 2032
5. Mayo Clinic - Haemophilus b conjugate vaccine (intramuscular route) - Mayo Clinic